This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2016 Feb;13(2):65.

doi: 10.1038/nrclinonc.2015.231. Epub 2015 Dec 31.

Haematological cancer: Ibrutinib paves way to a brighter future in MCL

PMID: 26718106
DOI: 10.1038/nrclinonc.2015.231

Comment

Haematological cancer: Ibrutinib paves way to a brighter future in MCL

David Killock. Nat Rev Clin Oncol. 2016 Feb.

. 2016 Feb;13(2):65.

doi: 10.1038/nrclinonc.2015.231. Epub 2015 Dec 31.

Author

PMID: 26718106
DOI: 10.1038/nrclinonc.2015.231

No abstract available

PubMed Disclaimer

Comment on

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. Dreyling M, et al. Lancet. 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4. Epub 2015 Dec 7. Lancet. 2016. PMID: 26673811 Clinical Trial.

References

1. Lancet. 2016 Feb 20;387(10020):770-8 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.